Chromosome 1 replacement increases brain orexins and antidepressive measures without increasing locomotor activity

Journal of Psychiatric Research

Volumn 59, Issue , 2014, Pages 140-147

  Feng, Pingfu ^a,b   Hu, Yufen ^a,b   Vurbic, Drina ^a   Akladious, Afaf ^b   Strohl, Kingman P ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Chromosome substitution; Depression; Immobility; Orexin

Indexed keywords

OREXIN A; OREXIN B; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CHROMOSOME 1; CHROMOSOME SUBSTITUTION; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; GENOTYPE; HYPOTHALAMUS; IMMOBILITY; LOCOMOTION; MALE; MEDULLA OBLONGATA; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RESPIRATION CONTROL; STRAIN DIFFERENCE; TAIL SUSPENSION TEST; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CATALEPSY; DISEASE MODEL; GENETICS; HUMAN; IMMOBILIZATION; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; SWIMMING;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CHROMOSOMES, HUMAN, PAIR 1; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; FREEZING REACTION, CATALEPTIC; HINDLIMB SUSPENSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROPEPTIDES; RADIOIMMUNOASSAY; SWIMMING;

EID: 84908325163     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.08.008     Document Type: Article

References (70)

1. Aksu K., Firat Guven S., Aksu F., Ciftci B., Ulukavak Ciftci T., Aksaray S., et al. Obstructive sleep apnoea, cigarette smoking and plasma orexin-A in a sleep clinic cohort. JInt Med Res 2009, 37:331-340.
2. Allard J.S., Tizabi Y., Shaffery J.P., Trouth C.O., Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 2004, 38:311-315.
3. Antunes V.R., Brailoiu G.C., Kwok E.H., Scruggs P., Dun N.J. Orexins/hypocretins excite rat sympathetic preganglionic neurons invivo and invitro. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1801-R1807.
4. Bachli H., Steiner M.A., Habersetzer U., Wotjak C.T. Increased water temperature renders single-housed C57BL/6J mice susceptible to antidepressant treatment in the forced swim test. Behav Brain Res 2008, 187:67-71.
5. Bourgin P., Huitron-Resendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. JNeurosci: Off J Soc Neurosci 2000, 20:7760-7765.
6. Boyle A.E., Gill K.J. Averification of previously identified QTLs for cocaine-induced activation using a panel of B6.A chromosome substitution strains (CSS) and A/J×C57Bl/6J F2 mice. Psychopharmacol Berl 2009, 207:325-334.
7. Brundin L., Bjorkqvist M., Petersen A., Traskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 2007, 17:573-579.
8. Busquets X., Barbe F., Barcelo A., de la Pena M., Sigritz N., Mayoralas L.R., et al. Decreased plasma levels of orexin-A in sleep apnea. Respiration 2004, 71:575-579.
9. Cai X.J., Lister C.A., Buckingham R.E., Pickavance L., Wilding J., Arch J.R., et al. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone. Brain Res Mol brain Res 2000, 77:131-137.
10. Cervo L., Canetta A., Calcagno E., Burbassi S., Sacchetti G., Caccia S., et al. Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression. JNeurosci: Off J Soc Neurosci 2005, 25:8165-8172.
11. Cowen P.J. Serotonin and depression: pathophysiological mechanism or marketing myth?. Trends Pharmacol Sci 2008, 29:433-436.
12. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29:547-569.
13. Daniels E., King M.A., Smith I.E., Shneerson J.M. Health-related quality of life in narcolepsy. JSleep Res 2001, 10:75-81.
14. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
15. de Oliveira C.V., Rosas-Arellano M.P., Solano-Flores L.P., Ciriello J. Cardiovascular effects of hypocretin-1 in nucleus of the solitary tract. Am J Physiol Heart Circ Physiol 2003, 284:H1369-H1377.
16. El Yacoubi M., Bouali S., Popa D., Naudon L., Leroux-Nicollet I., Hamon M., et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A 2003, 100:6227-6232.
17. Fava M. Daytime sleepiness and insomnia as correlates of depression. JClin Psychiatry 2004, 65(Suppl.16):27-32.
18. Feng P., Hu Y., Li D., Vurbic D., Fan H., Wang S., et al. The effect of clomipramine on wake/sleep and orexinergic expression in rats. JPsychopharmacol 2009, 23:559-566.
19. Feng P., Ma Y. Instrumental REM sleep deprivation in neonates leads to adult depression-like behaviors in rats. Sleep 2003, 26:990-996.
20. Feng P., Vurbic D., Wu Z., Hu Y., Strohl K. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. JPsychopharmacol 2008, 22:784-791.
21. Feng P., Vurbic D., Wu Z., Strohl K.P. Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res 2007, 1154:163-172.
22. Froese C.L., Butt A., Mulgrew A., Cheema R., Speirs M.A., Gosnell C., et al. Depression and sleep-related symptoms in an adult, indigenous, North American population. JClin Sleep Med 2008, 4:356-361.
23. Gershenfeld H.K., Neumann P.E., Mathis C., Crawley J.N., Li X., Paul S.M. Mapping quantitative trait loci for open-field behavior in mice. Behav Genet 1997, 27:201-210.
24. Han F., Mignot E., Wei Y.C., Dong S.X., Li J., Lin L., et al. Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J 2010, 36:577-583.
25. Han F., Subramanian S., Price E.R., Nadeau J., Strohl K.P. Periodic breathing in the mouse. JAppl Phys 2002, 92:1133-1140.
26. Hartley P., Neill D., Hagler M., Kors D., Vogel G. Procedure- and age-dependent hyperactivity in a new animal model of endogenous depression. Neurosci Biobehav Rev 1990, 14:69-72.
27. Haxhiu M.A., Mack S.O., Wilson C.G., Feng P., Strohl K.P. Sleep networks and the anatomic and physiologic connections with respiratory control. Front Biosci: J Virtual Libr 2003, 8:d946-d962.
28. Haynes A.C., Chapman H., Taylor C., Moore G.B., Cawthorne M.A., Tadayyon M., et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 2002, 104:153-159.
29. Ito N., Yabe T., Gamo Y., Nagai T., Oikawa T., Yamada H., et al. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 2008, 157:720-732.
30. Jones D.N., Gartlon J., Parker F., Taylor S.G., Routledge C., Hemmati P., et al. Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. Psychopharmacology 2001, 153:210-218.
31. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
32. Kessler R.C., Merikangass K.R. The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res 2004, 13:60-68.
33. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an invivo microdialysis and receptor binding study. Neuropsychopharmacology 2002, 27:949-959.
34. Kuwaki T. Orexinergic modulation of breathing across vigilance states. Respir Physiol Neurobiol 2008, 164:204-212.
35. Loyens E., De Bundel D., Demaegdt H., Chai S.Y., Vanderheyden P., Michotte Y., et al. Antidepressant-like effects of oxytocin in mice are dependent on the presence of insulin-regulated aminopeptidase. Int J Neuropsychopharmacol/Off Sci J Coll Int Neuropsychopharmacol 2013, 16:1153-1163.
36. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001, 155:315-322.
37. Lutter M., Krishnan V., Russo S.J., Jung S., McClung C.A., Nestler E.J. Orexin signaling mediates the antidepressant-like effect of calorie restriction. JNeurosci: Off J Soc Neurosci 2008, 28:3071-3075.
38. Machaalani R., Hunt N.J., Waters K.A. Effects of changes in energy homeostasis and exposure of noxious insults on the expression of orexin (hypocretin) and its receptors in the brain. Brain Res 2013, 1526:102-122.
39. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Psychopharmacology: the fourth generation of progress 1995, Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
40. Mazzocchi G., Malendowicz L.K., Gottardo L., Aragona F., Nussdorfer G.G. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. JClin Endocrinol Metabolism 2001, 86:778-782.
41. Methippara M.M., Alam M.N., Szymusiak R., McGinty D. Effects of lateral preoptic area application of orexin-A on sleep-wakefulness. Neuroreport 2000, 11:3423-3426.
42. Mikrouli E., Wortwein G., Soylu R., Mathe A.A., Petersen A. Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides 2011, 45:401-406.
43. Moore M.W., Akladious A., Hu Y., Azzam S., Feng P., Strohl K. Effects of orexin 2 receptor activation on apnea in the C57BL/6J mouse. Respir Physiol Neurobiol 2014, 200:118-125.
44. Murray J.L., Lopez A.D.L. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 1996, Harvard University Press, Cambridge, MA.
45. Nattie E., Li A. Respiration and autonomic regulation and orexin. Prog Brain Res 2012, 198:25-46.
46. Nishijima T., Sakurai S., Arihara Z., Takahashi K.P. Plasma orexin-A-like immunoreactivity in patients with sleep apnea hypopnea syndrome. Peptides 2003, 24:407-411.
47. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
48. Nocjar C., Zhang J., Feng P., Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience 2012, 218:138-153.
49. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
50. Piper D.C., Upton N., Smith M.I., Hunter A.J. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000, 12:726-730.
51. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
52. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
53. Randeva H.S., Karteris E., Grammatopoulos D., Hillhouse E.W. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. JClin Endocrinol Metab 2001, 86:4808-4813.
54. Renard C.E., Dailly E., Nic Dhonnchadha B.A., Hascoet M., Bourin M. Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test?. Prog Neuro-Psychopharmacol Biol Psychiatry 2004, 28:1255-1259.
55. Ripoll N., David D.J., Dailly E., Hascoet M., Bourin M. Antidepressant-like effects in various mice strains in the tail suspension test. Behav Brain Res 2003, 143:193-200.
56. Sakurai S., Nishijima T., Takahashi S., Yamauchi K., Arihara Z., Takahashi K. Clinical significance of daytime plasma orexin-A-like immunoreactivity concentrations in patients with obstructive sleep apnea hypopnea syndrome. Respiration 2004, 71:380-384.
57. Sakurai S., Nishijima T., Takahashi S., Yamauchi K., Arihara Z., Takahashi K. Low plasma orexin-A levels were improved by continuous positive airway pressure treatment in patients with severe obstructive sleep apnea-hypopnea syndrome. Chest 2005, 127:731-737.
58. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
59. Schmidt F.M., Arendt E., Steinmetzer A., Bruegel M., Kratzsch J., Strauss M., et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res 2011, 190:240-243.
60. Scott M.M., Marcus J.N., Pettersen A., Birnbaum S.G., Mochizuki T., Scammell T.E., et al. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res 2011, 222:289-294.
61. Singer J.B., Hill A.E., Burrage L.C., Olszens K.R., Song J., Justice M., et al. Genetic dissection of complex traits with chromosome substitution strains of mice. Science 2004, 304:445-448.
62. Smith P.M., Connolly B.C., Ferguson A.V. Microinjection of orexin into the rat nucleus tractus solitarius causes increases in blood pressure. Brain Res 2002, 950:261-267.
63. Sui Z.Y., Chae H.J., Huang G.B., Zhao T., Shrestha Muna S., Chung Y.C. Effects of chronic mild stress in female bax inhibitor-1-gene knockout mice. Clin Psychopharmacol Neurosci: Off Sci J Korean Coll Neuropsychopharmacol 2012, 10:155-162.
64. Thifault S., Lalonde R., Sanon N., Hamet P. Comparisons between C57BL/6J and A/J mice in motor activity and coordination, hole-poking, and spatial learning. Brain Res Bull 2002, 58:213-218.
65. Tomida S., Mamiya T., Sakamaki H., Miura M., Aosaki T., Masuda M., et al. Usp46 is a quantitative trait gene regulating mouse immobile behavior in the tail suspension and forced swimming tests. Nat Genet 2009, 41:688-695.
66. Vogel G., Neill D., Hagler M., Kors D. Anew animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 1990, 14:85-91.
67. Wang Y., He J., Kastin A.J., Hsuchou H., Pan W. Hypersomnolence and reduced activity in pan-leptin receptor knockout mice. JMol Neurosci: MN 2013, 51:1038-1045.
68. Wilson S., Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005, 65:927-947.
69. Yamauchi M., Kimura H., Strohl K.P. Mouse models of apnea: strain differences in apnea expression and its pharmacologic and genetic modification. Adv Exp Med Biol 2010, 669:303-307.
70. Yamauchi M., Ocak H., Dostal J., Jacono F.J., Loparo K.A., Strohl K.P. Post-sigh breathing behavior and spontaneous pauses in the C57BL/6J (B6) mouse. Respir Physiol Neurobiol 2008, 162:117-125.